BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bladder Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Bladder Cancer\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06829823-2051@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT06
 829823)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2\, Bladder Canc
 er.\nStudy: Clinical Trial of Ablation Therapy in Participants With Interm
 ediate-Risk Non-Muscle Invasive Papillary Bladder Cancer\nEstimated primar
 y completion: November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06829823
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02989584-1962@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT02989584)
DESCRIPTION:Atezolizumab\, phase 1/2\, Bladder Cancer.\nStudy: A Phase II S
 tudy of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Su
 rgery to Remove the Bladder Cancer\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02989
 584
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05000294-1962@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05000294)
DESCRIPTION:Atezolizumab\, phase 1/2\, Bladder Cancer.\nStudy: Atezolizumab
  Plus Tivozanib in Immunologically Cold Tumor Types\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05000294
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03915678-1962@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03915678)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: At
 ezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients W
 ith Advanced Solid Tumors\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03915678
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05756569-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT05756569)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Met
 astatic Bladder Cancer of Variant Histology\nEstimated primary completion:
  16 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/en
 fortumab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05756569
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04658862-2285@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cetrelimab: Phase 3 readout est. (NCT04658862)
DESCRIPTION:Cetrelimab\, phase 3\, Bladder Cancer.\nStudy: A Study of TAR-2
 00 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in P
 articipants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder\nEst
 imated primary completion: 30 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cetrelimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04658862
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03601455-1959@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03601455)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Radiation Therap
 y and Durvalumab With or Without Tremelimumab in Treating Participants Wit
 h Unresectable\, Locally Advanced\, or Metastatic Bladder Cancer\nEstimate
 d primary completion: 31 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03601455
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03601455-2015@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT03601455)
DESCRIPTION:Tremelimumab\, phase 2\, Bladder Cancer.\nStudy: Radiation Ther
 apy and Durvalumab With or Without Tremelimumab in Treating Participants W
 ith Unresectable\, Locally Advanced\, or Metastatic Bladder Cancer\nEstima
 ted primary completion: 31 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03601455
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04186013-1962@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04186013)
DESCRIPTION:Atezolizumab\, phase 2\, Bladder Cancer.\nStudy: Efficacy of At
 ezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive B
 ladder cáncer\nEstimated primary completion: February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04186013
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04724018-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT04724018)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: Sacitu
 zumab Govitecan Plus EV in Metastatic UC\nEstimated primary completion: 1 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enfort
 umab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04724018
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04106115-1959@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT04106115)
DESCRIPTION:Durvalumab\, phase 1/2\, Bladder Cancer.\nStudy: DURvalumab in 
 Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder 
 CancEr\nEstimated primary completion: 30 March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04106115
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768570-1959@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03768570)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Trimodality Ther
 apy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Can
 cer\nEstimated primary completion: 31 March 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03768570
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647289-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07647289)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: EV + Tor
 ipalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC\n
 Estimated primary completion: April 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07647289
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06305767-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270423
DTEND;VALUE=DATE:20270424
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT06305767)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: A Clin
 ical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in Pe
 ople With Bladder Cancer (V940-005/INTerpath-005)\nEstimated primary compl
 etion: 23 April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /enfortumab-vedotin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06305767
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05239624-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT05239624)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin and Pembrolizumab in People With Bladder Cancer\nEstimated prim
 ary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05239624
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07332351-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07332351)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Neoadjuv
 ant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pemb
 rolizumab for the Treatment of Muscle Invasive Bladder Cancer\, TRIFECTA T
 rial\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07332351
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03237780-1962@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03237780)
DESCRIPTION:Atezolizumab\, phase 2\, Bladder Cancer.\nStudy: Atezolizumab W
 ith or Without Eribulin Mesylate in Treating Patients With Recurrent Local
 ly Advanced or Metastatic Urothelial Cancer\nEstimated primary completion:
  30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03237780
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222488-11234@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:MK-3120: Phase 1/2 readout est. (NCT07222488)
DESCRIPTION:MK-3120\, phase 1/2\, Bladder Cancer.\nStudy: A Clinical Study 
 of MK-3120 in People With Bladder Cancer (MK-3120-003)\nEstimated primary 
 completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/mk-3120#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07222488
URL:https://assetmemo.bio/drug/mk-3120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06263153-1959@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06263153)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Futibatinib in C
 ombination With Durvalumab Prior to Cystectomy for the Treatment of Muscle
 -Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based T
 herapy\nEstimated primary completion: 31 July 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06263153
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06434350-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT06434350)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: Enfort
 umab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDA
 TE)\nEstimated primary completion: 24 September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06434350
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05312671-1962@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05312671)
DESCRIPTION:Atezolizumab\, phase 2\, Bladder Cancer.\nStudy: Atezolizumab P
 lus Etoposide and Platinum in Small Cell Bladder Cancer\nEstimated primary
  completion: October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05312671
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06588179-11097@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:SHR-2005: Phase 1/2 readout est. (NCT06588179)
DESCRIPTION:SHR-2005\, phase 1/2\, Bladder Cancer.\nStudy: SHR-1501 Combine
 d With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is 
 Not Completely Resectable by TURBt\nEstimated primary completion: 1 Octobe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-2005#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06588179
URL:https://assetmemo.bio/drug/shr-2005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06809140-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06809140)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment
  of Muscle-invasive Bladder Cancer\nEstimated primary completion: November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/enfortumab-ved
 otin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06809140
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07475806-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07475806)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: A Study 
 to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People Wi
 th Muscle-invasive Bladder Cancer Keep Their Bladder\nEstimated primary co
 mpletion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07475806
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06503614-1959@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20271222
DTEND;VALUE=DATE:20271223
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06503614)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: A Trial of Durva
 lumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer\nE
 stimated primary completion: 22 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06503614
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780838-1959@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07780838)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Alternating Chem
 o-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangioc
 arcinoma\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07780838
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06470282-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT06470282)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: Enfort
 umab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasi
 ve Bladder Cancer\nEstimated primary completion: 31 January 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06470282
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05656235-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT05656235)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Renal Re
 tention in High Grade Upper Tract Urothelial Cancer\nEstimated primary com
 pletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 nfortumab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05656235
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087860-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07087860)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Therapeu
 tic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatmen
 t of Bladder Cancers\nEstimated primary completion: 7 August 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07087860
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06960577-1959@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06960577)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Perioperative Du
 rvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder 
 Cancer (NIAGARA-2)\nEstimated primary completion: 30 August 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06960577
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137262-1959@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05137262)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: A Phase II Multi
 center Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 473
 6) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladde
 r\nEstimated primary completion: 31 August 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05137262
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06394570-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT06394570)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: Enfort
 umab Vedotin and Stereotactic Radiation for Localized Bladder Cancer\nEsti
 mated primary completion: 30 September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06394570
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662863-1991@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07662863)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Bladder Cancer.\nStudy: Sac
 ituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-
 SPARE-UC-01)\nEstimated primary completion: 1 December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07662863
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03317158-1959@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03317158)
DESCRIPTION:Durvalumab\, phase 1/2\, Bladder Cancer.\nStudy: Modern Immunot
 herapy in BCG-Unresponsive\, BCG-Relapsing and High Risk BCG-Naive Non-Mus
 cle Invasive Urothelial Carcinoma of the Bladder\nEstimated primary comple
 tion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03317158
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03317158-2015@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tremelimumab: Phase 1/2 readout est. (NCT03317158)
DESCRIPTION:Tremelimumab\, phase 1/2\, Bladder Cancer.\nStudy: Modern Immun
 otherapy in BCG-Unresponsive\, BCG-Relapsing and High Risk BCG-Naive Non-M
 uscle Invasive Urothelial Carcinoma of the Bladder\nEstimated primary comp
 letion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tremelimumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03317158
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643519-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07643519)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Neoadjuv
 ant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cance
 r and Upper Tract Urothelial Carcinoma\nEstimated primary completion: Febr
 uary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enfortumab
 -vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07643519
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667335-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20290716
DTEND;VALUE=DATE:20290717
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07667335)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: Enfort
 umab Vedotin\, Pembrolizumab and Quemliclustat for the Treatment of Unrese
 ctable Locally Advanced and Metastatic Urothelial Cancer\nEstimated primar
 y completion: 16 July 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07667335
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06214572-1959@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20290721
DTEND;VALUE=DATE:20290722
SUMMARY:Durvalumab: Phase 2/3 readout est. (NCT06214572)
DESCRIPTION:Durvalumab\, phase 2/3\, Bladder Cancer.\nStudy: Radiation Ther
 apy in Unresectable Gall Bladder Cancer\nEstimated primary completion: 21 
 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062
 14572
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07419295-1991@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20290727
DTEND;VALUE=DATE:20290728
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07419295)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Bladder Cancer.\nStudy: A C
 linical Trial of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) to Treat Urot
 helial Cancer (MK-2870-031)\nEstimated primary completion: 27 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumoteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 419295
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714202-2285@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20290918
DTEND;VALUE=DATE:20290919
SUMMARY:Cetrelimab: Phase 3 readout est. (NCT05714202)
DESCRIPTION:Cetrelimab\, phase 3\, Bladder Cancer.\nStudy: A Study of TAR-2
 00 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bac
 illus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non
 -muscle Invasive Bladder Cancer (HR-NMIBC)\nEstimated primary completion: 
 18 September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ce
 trelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05714202
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908979-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07908979)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Risk-Ena
 bled Therapy After Initiating EV/Pembro for Bladder Cancer\nEstimated prim
 ary completion: 1 October 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07908979
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566156-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Enfortumab Vedotin: Phase 3 readout est. (NCT07566156)
DESCRIPTION:Enfortumab Vedotin\, phase 3\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiother
 apy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)\nEstimat
 ed primary completion: 31 March 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07566156
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07346053-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Enfortumab Vedotin: Phase 3 readout est. (NCT07346053)
DESCRIPTION:Enfortumab Vedotin\, phase 3\, Bladder Cancer.\nStudy: The Impa
 ct of Time-of-day Administration of EV/P on Objective Response Rate in Adu
 lts With Advanced Bladder Cancer\nEstimated primary completion: December 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedot
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7346053
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07663747-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20310401
DTEND;VALUE=DATE:20310402
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07663747)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC\nEstimat
 ed primary completion: 1 April 2031. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07663747
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232602-2121@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20310708
DTEND;VALUE=DATE:20310709
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07232602)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: KEYMAK
 ER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortu
 mab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04
 D/KEYMAKER-U04)\nEstimated primary completion: 8 July 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07232602
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232602-11234@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20310708
DTEND;VALUE=DATE:20310709
SUMMARY:MK-3120: Phase 1/2 readout est. (NCT07232602)
DESCRIPTION:MK-3120\, phase 1/2\, Bladder Cancer.\nStudy: KEYMAKER-U04 Subs
 tudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin
  and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-
 U04)\nEstimated primary completion: 8 July 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/mk-3120#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07232602
URL:https://assetmemo.bio/drug/mk-3120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829783-1991@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20311117
DTEND;VALUE=DATE:20311118
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07829783)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Bladder Cancer.\nStudy: A C
 linical Trial of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) and Pembroliz
 umab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)\nEstimat
 ed primary completion: 17 November 2031. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07829783
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829783-2259@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20311117
DTEND;VALUE=DATE:20311118
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT07829783)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3\
 , Bladder Cancer.\nStudy: A Clinical Trial of Sacituzumab Tirumotecan (Sac
 -TMT\, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder 
 Cancer (MK-2870-055)\nEstimated primary completion: 17 November 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab-berahyaluro
 nidase-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07829783
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
